Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02428608
Other study ID # Evolus - CLIN006
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2015
Est. completion date November 2016

Study information

Verified date April 2019
Source Evolus, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult subjects.


Description:

Up to five hundred and thirty (530) subjects will be enrolled and injected with the study drug DWP-450 over the course of the 365 day study.

Subjects with moderate-to-severe glabellar lines at maximum frown on the 4 point Glabellar Line Scale (GLS, 0=none, 1= mild, 2=moderate, 3=severe), as judged by the investigator, will be eligible for injection with DWP-450.

Subjects may receive up to a maximum of 4 treatments and will be followed for 365 days from initial treatment.


Recruitment information / eligibility

Status Completed
Enrollment 570
Est. completion date November 2016
Est. primary completion date October 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects must be an adult 18 years of age and over

- Subject is able to provide informed consent and comply with study instructions

- Subject has moderate-to-severe glabellar lines on maximum frown as assessed by the investigator and subject using the GLS

- Subject is willing and able to complete the entire course of the study

Exclusion Criteria:

- Previous treatment with botulinum toxin of any serotype in any area within the last 6 months

- Previous treatment with any facial aesthetic procedure (e.g. injection with fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months

- Previous insertion of permanent material in the glabellar area

- Planned treatment with botulinum toxin of any serotype in any other body region during the study period

- Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area and the surrounding areas (including eye brow)

- Energy based or cryo-therapy based treatment of facial muscles superior to the lateral canthus

- Any other planned facial aesthetic procedure during the trial period, superior to the level of the lateral canthus (subjects can continue with their usual skin care routine)

- Inability to substantially lessen glabellar frown lines even by physically spreading them apart

- Marked facial asymmetry

- Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis

- History of facial nerve palsy

- Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin

- Any active infection in the area of the injection sites

- Medical condition that may affect neuromuscular function (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis)

- Evidence of recent alcohol or drug abuse

- Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study

- Pregnant, nursing or sexually active female subjects who are of childbearing potential and who are not willing to use an acceptable form of contraception

- Known allergy or hypersensitivity to botulinum toxin preparation

- Participation in another interventional clinical study within the last 30 days

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
DWP-450 (Botulinum purified neurotoxin, Type A)
Botulinum toxin, Type A

Locations

Country Name City State
United States The Advanced Skin Research Center at Skin Specialists, PC Omaha Nebraska

Sponsors (2)

Lead Sponsor Collaborator
Evolus, Inc. PPD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change From Baseline Glabellar Line Scale (GLS) Score at Rest and at Maximum Frown Proportion of subjects with an improvement of 1 point or more (i.e., =1 point responders) on the GLS at rest at end of study/early termination: by Investigator assessment 365 days
Primary The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365. 365 days
See also
  Status Clinical Trial Phase
Completed NCT02236312 - Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines Phase 2
Active, not recruiting NCT05565950 - AI-09 In Subjects With Glabellar Lines, GL-101 Phase 1/Phase 2
Completed NCT00430963 - IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines Phase 3
Recruiting NCT05083286 - Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines Early Phase 1
Completed NCT03687736 - Subject Satisfaction With AbobutulinumtoxinA Treatment Phase 4
Active, not recruiting NCT04281745 - Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® Phase 4
Active, not recruiting NCT05623410 - Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines Phase 3
Active, not recruiting NCT03440671 - The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines Phase 3
Completed NCT03736928 - Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines Phase 2
Completed NCT01808742 - Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device N/A
Completed NCT00777803 - NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines Phase 3
Completed NCT00430586 - Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines Phase 2
Completed NCT04281095 - A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines Phase 1/Phase 2
Completed NCT05146999 - Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines Phase 3
Completed NCT04143815 - Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines Phase 2
Not yet recruiting NCT05305768 - Xeomin Treatment of Glabellar Lines Using OLD Versus COLD Early Phase 1
Completed NCT05364580 - The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines Phase 3
Completed NCT05320393 - Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines Phase 2
Completed NCT02677805 - Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II Phase 3
Completed NCT01333397 - Safety and Efficacy Study of Dysport RU and Glabellar Lines Phase 2